PIA
OVID icon

Piedmont Investment Advisors’s Ovid Therapeutics OVID Stock Holding History

Piedmont Investment Advisors’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-229
Closed -$2K – 1908
2018
Q2 		$2K Buy
+229
New +$1.97K ﹤0.01% 2613

Other funds holding OVID

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Piedmont Investment Advisors's OVID Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Ovid Therapeutics (OVID) in Q3 2018, closing a stake of 229 shares — an estimated $2K sold.

Piedmont Investment Advisors first reported a position in OVID in Q2 2018 and held it in 1 quarter. The position peaked at $2K in Q2 2018. 49 funds tracked by Wall St. Rank hold OVID as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Ovid Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 229 Ovid Therapeutics shares in Q3 2018, an estimated $2K.
  • Piedmont Investment Advisors first reported a position in Ovid Therapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Ovid Therapeutics position peaked at $2K in Q2 2018.
  • 49 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.